Company / Cash & Equivalents
SI-BONE, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$42.2M
FY2025
5-year range
$20.7M / $63.4M
FY2021-FY2025
Trend
+20.9%
vs FY2024
Sector context
#136 of 152
Health Care
What the data says
SI-BONE, Inc.'s cash & equivalents of $42M is lower than 89% of companies in the Health Care sector (FY2025). Cash & Equivalents has increased for 3 consecutive years, from $21M in FY2022 to $42M in FY2025.
Based on SEC 10-K filings.
$42M in FY2025 with a 5-year CAGR of -4.6%.
Improved from $33M to $42M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +26.8%
- 5-Year CAGR
- -4.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 152This company $42.2M Sector average $1.2B
▼
-96.4% below sector average
Key checks
Key Insights
- SI-BONE, Inc.'s cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of -4.6%, indicating a declining trend.
- In FY2025, cash & equivalents increased 20.9% year-over-year.
- Ranks #136 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.75 (distress zone, below 1.8 threshold)
- Negative profit margin: -18.5%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $42.2M | +20.9% |
| FY2024 | $34.9M | +5.0% |
| FY2023 | $33.3M | +60.6% |
| FY2022 | $20.7M | -67.3% |
| FY2021 | $63.4M | +18.4% |
| FY2020 | $53.6M | +413.5% |
| FY2019 | $10.4M | -58.5% |
| FY2018 | $25.1M | +12.1% |
| FY2017 | $22.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026